Acrivon Therapeutics, Inc. Common Stock (ACRV) - Total Liabilities
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has total liabilities worth $16.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Acrivon Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Acrivon Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Acrivon Therapeutics, Inc. Common Stock's balance sheet.
Acrivon Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SDS Group Bhd
KLSE:0212
|
Malaysia | RM73.84 Million |
|
JC Chemical Co. Ltd
KQ:137950
|
Korea | ₩265.18 Billion |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
Taiwan | NT$1.36 Billion |
|
Gray Television Inc
NYSE:GTN-A
|
USA | $7.56 Billion |
|
Bina Puri Holdings Bhd
KLSE:5932
|
Malaysia | RM645.26 Million |
|
Bilendi
PA:ALBLD
|
France | €100.55 Million |
|
Fire & Gas Detection Technologies Ltd
TA:FGAS
|
Israel | ILA41.79 Million |
|
Hansol Csn
KO:009180
|
Korea | ₩123.82 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Acrivon Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ACRV equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acrivon Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.80 Million | +16.00% |
| 2023-12-31 | $17.07 Million | +58.78% |
| 2022-12-31 | $10.75 Million | -91.76% |
| 2021-12-31 | $130.40 Million | +1130.38% |
| 2020-12-31 | $10.60 Million | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more